When does Praluent (alirocumab) lose patent protection?
Praluent’s U.S. patent landscape is tied to drug- and product-specific intellectual property, so “off patent” depends on which patent is being considered (for example, method-of-use vs. composition claims). Public patent listings also track when generic or biosimilar-style competition might become possible, but actual launch timing can be delayed by patent challenges and litigation.
A practical way to check the most relevant exclusivity and patent expiry dates for Praluent is through DrugPatentWatch, which compiles patent-expiration timelines for branded products: https://www.drugpatentwatch.com/patent/Praluent
Are there generics or biosimilars for Praluent already?
Because Praluent is a biologic (an antibody), the market typically does not see “small-molecule” generics. Instead, the key competition question is whether any approved biosimilar (or other legally authorized alternative) can enter based on when patent and regulatory exclusivity barriers clear.
To verify what’s available (and what’s still blocked by patents), check the current status and pipeline details on DrugPatentWatch for Praluent: https://www.drugpatentwatch.com/patent/Praluent
What determines the real “off patent” date in practice?
Even after a particular patent expires, other patents can still block entry, depending on:
- Which patents cover the drug product (not just the active ingredient)
- Whether companies win or lose patent litigation
- Whether regulatory exclusivity periods run alongside patents
That’s why two sources may show different “earliest possible competition” dates unless they refer to the same specific patent set.
How can I find the exact Praluent patent that blocks the market?
If you want the most direct answer for “off patent,” you need the specific patent family and its expiry date(s). DrugPatentWatch lets you filter by product and related patents and view the expiration timeline used for market-entry forecasting: https://www.drugpatentwatch.com/patent/Praluent
If you tell me your country, I can narrow it down
Patent and exclusivity timing varies by jurisdiction (U.S., EU, etc.). If you share the country you care about (and whether you mean “earliest possible competitor launch” or “the last relevant patent expiry”), I can help interpret the timeline from the relevant patents.
Sources
- https://www.drugpatentwatch.com/patent/Praluent